inWhite tw_white-black
MoreMenu
CloseWhite
inWhite tw_white-black

News

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer

Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

Cristiana Pires CEO discusses the increasing traction of cellular reprogramming within the investor community in Portuguese newspaper Expresso.

Posted 25 January, 2022